The Institute for Clinical and Economic Review (ICER) cordially invites you to learn about the ICER Value Assessment Framework.
With prices of new prescription drugs a growing problem, one impediment to progress has been the lack of an adequate infrastructure to produce independent, publicly available analyses of the comparative effectiveness of the new drugs at the time of their introduction. Insurers, provider groups, patients, policy makers – and manufacturers themselves – all need a trustworthy source for this information to anchor discussions regarding appropriate use, pricing, and payment for new drugs.
The ICER Value Assessment Framework is a component of ICER’s new drug assessment program. The framework fills a critical gap in the analyses done as part of the program and is used to calculate, in an objective, transparent fashion, a “value-based price benchmark.”
Join ICER’s President and Founder Steven D. Pearson, MD, MSc, on Tuesday, September 15th to learn more about ICER’s Value Assessment Framework. He will be joined by Robert W. Dubois, MD, PhD, Chief Science Officer of the National Pharmaceutical Council, who will present his views of the framework.
Registration is free. The public (including media) are welcome to attend, and a replay of the webinar will be available on the ICER website.